KLK3 and prostate cancer: To further distinguish prostate cancer patients with PSA > 4.0 ng/mL and PSA < 4.0 ng/mL, our results confirmed that the serum content of pyroglutamic was higher in patients with PSA < 4.0 ng/mL than in patients with PSA > 4.0 ng/mL.